CU24103B1 - Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos - Google Patents

Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos

Info

Publication number
CU24103B1
CU24103B1 CU2012000021A CU20120021A CU24103B1 CU 24103 B1 CU24103 B1 CU 24103B1 CU 2012000021 A CU2012000021 A CU 2012000021A CU 20120021 A CU20120021 A CU 20120021A CU 24103 B1 CU24103 B1 CU 24103B1
Authority
CU
Cuba
Prior art keywords
pharmaceutically acceptable
spirocycles
same
salts pharmaceutically
amido
Prior art date
Application number
CU2012000021A
Other languages
English (en)
Other versions
CU20120021A7 (es
Inventor
Lilian Alcaraz
Andrew Bailey
Nicholas Kindon
Original Assignee
Astrazeneca Ab
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41129405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU24103(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Pulmagen Therapeutics Synergy filed Critical Astrazeneca Ab
Publication of CU20120021A7 publication Critical patent/CU20120021A7/es
Publication of CU24103B1 publication Critical patent/CU24103B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invención refiere a un compuesto de fórmula: o una sal faramcéuticamente aceptable del mismo y a un compuesto de fórmula: Dichos compuestos de la presente invención y sus sales son útiles en el tratamiento de enfermedades inflamatorias, como por ejemplo la artritis reumatoide, la osteoartritis, el asma, la rinitis alérgica, la enfermedad pulmonar obstructiva crónica (EPOC), la psoriasis y la enfermedad inflamatoria de los intestinos.
CU2012000021A 2009-07-31 2010-07-29 Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos CU24103B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0913342.2A GB0913342D0 (en) 2009-07-31 2009-07-31 Compounds - 801
PCT/GB2010/051242 WO2011012896A2 (en) 2009-07-31 2010-07-29 Compounds - 801

Publications (2)

Publication Number Publication Date
CU20120021A7 CU20120021A7 (es) 2012-06-21
CU24103B1 true CU24103B1 (es) 2015-07-30

Family

ID=41129405

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2012000021A CU24103B1 (es) 2009-07-31 2010-07-29 Compuestos derivados amido espirocíclicos y sales farmacéuticamente aceptable de los mismos

Country Status (33)

Country Link
US (2) US8455483B2 (es)
EP (1) EP2459572B1 (es)
JP (1) JP5612092B2 (es)
KR (1) KR101664525B1 (es)
CN (1) CN102625808B (es)
AR (1) AR080601A1 (es)
AU (1) AU2010277384B2 (es)
BR (1) BR112012008043A2 (es)
CA (1) CA2768527C (es)
CL (1) CL2012000263A1 (es)
CO (1) CO6491034A2 (es)
CR (1) CR20120054A (es)
CU (1) CU24103B1 (es)
DO (1) DOP2012000032A (es)
EA (1) EA020566B1 (es)
ES (1) ES2702467T3 (es)
GB (1) GB0913342D0 (es)
GT (1) GT201200028A (es)
HN (1) HN2012000217A (es)
IL (1) IL217557A (es)
MX (1) MX2012001232A (es)
MY (1) MY163117A (es)
NI (1) NI201200018A (es)
NZ (1) NZ597589A (es)
PE (1) PE20121441A1 (es)
SA (1) SA110310628B1 (es)
SG (1) SG177634A1 (es)
TR (1) TR201819140T4 (es)
TW (1) TWI443103B (es)
UA (1) UA106887C2 (es)
UY (1) UY32814A (es)
WO (1) WO2011012896A2 (es)
ZA (1) ZA201201473B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101273200B1 (ko) 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
GB201021992D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab New compound
WO2016179349A1 (en) * 2015-05-05 2016-11-10 Northwestern University Cxcr4 chemokine receptor modulators
WO2018059537A1 (zh) * 2016-09-30 2018-04-05 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途
JP6963616B2 (ja) 2016-12-14 2021-11-10 ベイジン ショウバイ ファーマシューティカル カンパニー，リミティッド ４級アンモニウム塩構造を有する二官能性化合物
CN110678463B (zh) 2017-06-01 2023-06-06 百时美施贵宝公司 经取代的含氮化合物
EP3682906A1 (en) * 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707186A (en) 1954-05-06 1955-04-26 Hoffmann La Roche Imidazolone derivatives
AU565621B2 (en) 1983-04-26 1987-09-24 Smithkline Beckman Corporation Dopaminergic carbostyrils
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9604578D0 (en) 1996-03-04 1996-05-01 Sericol Ltd Photocurable compositions
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
BR0112224A (pt) 2000-07-07 2003-06-10 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
JP4846709B2 (ja) 2004-03-10 2011-12-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ５員複素環で置換されているｍｔｐ阻害性アリールピペリジン若しくはピペラジン
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US20050215542A1 (en) 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
JP2008516939A (ja) 2004-10-15 2008-05-22 アストラゼネカ アクチボラグ 化学化合物
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
ATE516026T1 (de) 2005-02-21 2011-07-15 Shionogi & Co Bicyclisches carbamoylpyridonderivat mit hiv- integrase-hemmender wirkung
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
EP1961744B1 (en) * 2005-11-18 2013-04-17 Ono Pharmaceutical Co., Ltd. Basic group-containing compound and use thereof
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
AU2007284548A1 (en) * 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
US20100056508A1 (en) * 2006-12-20 2010-03-04 Astrazeneca Ab Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
GB0702413D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
KR101273200B1 (ko) * 2008-02-06 2013-06-17 펄마젠 쎄라퓨틱스 (시너지) 리미티드 화합물
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801

Also Published As

Publication number Publication date
AR080601A1 (es) 2012-04-25
CU20120021A7 (es) 2012-06-21
MY163117A (en) 2017-08-15
NI201200018A (es) 2012-09-10
ZA201201473B (en) 2012-11-28
EP2459572B1 (en) 2018-09-12
JP2013500958A (ja) 2013-01-10
EA201290077A1 (ru) 2012-08-30
WO2011012896A2 (en) 2011-02-03
CL2012000263A1 (es) 2012-08-31
EA020566B1 (ru) 2014-12-30
EP2459572A2 (en) 2012-06-06
TWI443103B (zh) 2014-07-01
CO6491034A2 (es) 2012-07-31
US20110053909A1 (en) 2011-03-03
TW201107335A (en) 2011-03-01
UY32814A (es) 2011-02-28
US20130018037A1 (en) 2013-01-17
HN2012000217A (es) 2015-03-09
TR201819140T4 (tr) 2019-01-21
ES2702467T3 (es) 2019-03-01
GB0913342D0 (en) 2009-09-16
KR20120056838A (ko) 2012-06-04
WO2011012896A3 (en) 2011-04-21
MX2012001232A (es) 2012-03-26
CA2768527C (en) 2017-07-11
NZ597589A (en) 2013-12-20
SA110310628B1 (ar) 2014-02-27
BR112012008043A2 (pt) 2020-08-25
JP5612092B2 (ja) 2014-10-22
GT201200028A (es) 2013-09-26
AU2010277384B2 (en) 2014-01-30
CN102625808B (zh) 2014-08-27
KR101664525B1 (ko) 2016-10-11
PE20121441A1 (es) 2012-11-16
CA2768527A1 (en) 2011-02-03
DOP2012000032A (es) 2017-08-15
US8455483B2 (en) 2013-06-04
UA106887C2 (uk) 2014-10-27
IL217557A0 (en) 2012-02-29
CR20120054A (es) 2012-03-26
US8476265B2 (en) 2013-07-02
SG177634A1 (en) 2012-02-28
CN102625808A (zh) 2012-08-01
IL217557A (en) 2015-01-29
HK1171755A1 (en) 2013-04-05
AU2010277384A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1122639T1 (el) Παραγωγα 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου ως ενδιαμεσα στην παρασκευη παραγωγων [(5-αλογονοφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)- αμινο]αλκανοϊκου οξεος
GT200900289A (es) Compuestos organicos.-
CY1117580T1 (el) Νεα ετεροκυκλικα παραγωγα και η χρηση τους στη θεραπεια νευρολογικων διαταραχων
CY1118610T1 (el) Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου
UY32082A (es) Nuevas benzamidas, su preparación y su uso como medicamentos
SMT201300043B (it) Inibitori del virus dell'epatite c
EA201290296A1 (ru) Циклические пептиды, специфичные к рецептору меланокортина-1
CY1116791T1 (el) 4-αρυλ-ν-φαινυλ-1,3,5-τριαζιν-αμινες που περιεχουν μια ομαδα σουλφοξιμινης
EA201490357A1 (ru) Индазолы
UY34285A (es) Nuevos sulfóxidos de piperidino-dihidrotienopirimidina y su uso para tratar epoc y asma
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CR20140238A (es) Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc
CO6321265A2 (es) Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso
ECSP16079730A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
CO6801794A2 (es) Derivados de isoxazolina en el tratamiento de ectoparasitos y su proceso de producción
ECSP13012862A (es) Terapéuticos a base de levadura para infección de la hepatitis b crónica
UY31607A1 (es) Derivados bicíclicos de carboxamidas aza-bicíclicas, su preparación y su aplicación terapéutica
CY1120974T1 (el) Ετεροκυκλικες ενωσεις, φαρμακα που περιεχουν τις αναφερομενες ενωσεις, χρηση αυτων και διαδικασιες για την παραγωγη τους
CO6680645A2 (es) Inhibidores de oxadiazol de la producción de leucotrieno
CL2013003512A1 (es) Compuestos derivados de 7-(heterociclilo, arilo o heteroarilo) de piridopirazinas o sus sales; composicion farmaceutica que los comprende, utiles para el tratamiento de una enfermedad mediada por ptk quinasa tales como asma alergica, rinitis alergica, artritis reumatoide, esclerosis multiple, lupus, leucopenia, entre otras enfermedades.
EP2798063A4 (en) PREPARATION OF DIHYDROSTERCULINIC ACID AND DERIVATIVES THEREOF
BR112013030264A2 (pt) ácidos acéticos de benzociclohepteno
CL2017000478A1 (es) Compuesto de pirazolotiazol y medicamento que comprende el mismo.
HUE036319T2 (hu) 2-karboxamid-cikloamino-karbamidszármazékok szintézise

Legal Events

Date Code Title Description
FG Grant of patent